Congress needs to give the U.S. Health Resources and Services Administration (HRSA) comprehensive regulatory authority over the 340B program to resolve the dispute over the 340B contract pharmacy program, the Biden administration said yesterday in its proposed budget—although it did
…
Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
Community Health Centers of Arkansas (CHCA) filed the motion yesterday along with
…
Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.
BioComp, a wholly-owned subsidiary of San
…
Ryan White Clinics for 340B Access (RWC-340B) and its management services consultant have chosen Trent Smith, a former manager and director in both the nonprofit and for-profit sectors, to be RWC-340B’s new managing director.
RWC-340B announced the hiring last week.
…
The federal government has decided to intervene in a whistleblower lawsuit that accuses a Tennessee health system of paying Memphis-area cancer physicians for referrals that allegedly generated about $70 million a year in profits for the health system from billings
…
UPDATE Thursday, March 24, 2022, 2:10 p.m.—A Gilead spokesperson disputed AIDS Healthcare Foundation’s statement that, under Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments, the company will give 340B discounts to covered entities only
…
Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
BMS posted the refund notice on the U.S. Health Resources and Services Administration
…
California health centers told a federal judge last week that the state’s arguments for dismissing the centers’ lawsuit to reverse a new state Medicaid policy that deprives them of millions of dollars in 340B drug reimbursement lack merit.
Community Health
…
Yesterday, we broke the news that Johnson & Johnson announced conditions on 340B drug sales to hospitals on a host of pharmacy inventory staples including immunosuppressants, monoclonal antibodies, blood thinners, and treatments for diabetes, cancer, HIV, mental disorders, pulmonary
…
Requiring drug manufacturers “to sell to contract pharmacies at the 340B discount is price-fixing,” an influential source of model bills for conservative state lawmakers says in a new post on its website.
“Legislators understandably worry about the cost of prescription
…*Sign up for news summaries and alerts from 340B Report